{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:09:12Z","timestamp":1760015352290,"version":"3.37.3"},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T00:00:00Z","timestamp":1408665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100000276","name":"UK Department of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Research Council"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UK Department for International Development"},{"name":"BI"},{"name":"BMS"},{"name":"GSK"},{"name":"Merck"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gilead"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Viral hepatitis is responsible for great health, social and economic burden both globally and in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>. This study aimed to assess the research funding awarded to <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> institutions for viral hepatitis research and the relationship of funded research to clinical and public health burden of viral hepatitis. Databases and websites were systematically searched for information on infectious disease research studies funded for the period 1997\u20132010. Studies specifically related to viral hepatitis research were identified and categorized in terms of funding by pathogen, disease and by a research and development value chain describing the type of science. The overall data set included 6165 studies (total investment \u00a32.6 billion) of which \u00a376.9 million (3.0%) was directed towards viral hepatitis across 323 studies (5.2%). By pathogen, there were four studies specifically investigating hepatitis A (\u00a33.8 million), 69 studies for hepatitis B (21.4%) with total investment of \u00a314.7 million (19.1%) and 236 (73.1%) hepatitis C studies (\u00a362.7 million, 81.5%). There were 4 studies investigating hepatitis G, and none specifying hepatitis D or E. By associated area, viral hepatitis and therapeutics research received \u00a317.0 million, vaccinology \u00a33.1 million and diagnostics \u00a32.9 million. Preclinical research received \u00a350.3 million (65.4%) across 173 studies, whilst implementation and operational research received \u00a319.4 million (25.3%) across 128 studies. The <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> is engaged in much hepatology research, but there are areas where the burden is great and may require greater focus, such as hepatitis E, development of a vaccine for hepatitis C, and further research into hepatitis\u2010associated cancers. Private sector data, and funding information from other countries, would also be useful in priority setting.<\/jats:p>","DOI":"10.1111\/jvh.12300","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T09:19:34Z","timestamp":1408699174000},"page":"230-237","source":"Crossref","is-referenced-by-count":2,"title":["Systematic analysis of funding awarded for viral hepatitis\u2010related research to institutions in the <scp>U<\/scp>nited <scp>K<\/scp>ingdom, 1997\u20132010"],"prefix":"10.1111","volume":"22","author":[{"given":"M. G.","family":"Head","sequence":"first","affiliation":[{"name":"Research Department of Infection and Population Health University College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Fitchett","sequence":"additional","affiliation":[{"name":"Department for Infectious Diseases King's College London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. S.","family":"Cooke","sequence":"additional","affiliation":[{"name":"Infectious Diseases Imperial College London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. R.","family":"Foster","sequence":"additional","affiliation":[{"name":"Blizard Institute Queen Marys University of London London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Atun","sequence":"additional","affiliation":[{"name":"Harvard School of Public Health Harvard University Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_10_2_1","DOI":"10.1016\/j.vaccine.2010.08.037"},{"doi-asserted-by":"publisher","key":"e_1_2_10_3_1","DOI":"10.1093\/cid\/cit642"},{"issue":"21","key":"e_1_2_10_4_1","article-title":"World Hepatitis Day: a timely reminder of the challenges ahead","volume":"13","author":"Laar MJW","year":"2008","journal-title":"Euro Surveill"},{"doi-asserted-by":"publisher","key":"e_1_2_10_5_1","DOI":"10.1046\/j.1365-2893.2003.00487.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_6_1","DOI":"10.1002\/hep.25505"},{"volume-title":"Hepatitis B and C in the EU Neighbourhood: Prevalence, Burden of Disease and Screening Policies","year":"2010","author":"European Centre for Disease Prevention and Control","key":"e_1_2_10_7_1"},{"doi-asserted-by":"publisher","key":"e_1_2_10_8_1","DOI":"10.1017\/S0950268809002143"},{"doi-asserted-by":"publisher","key":"e_1_2_10_9_1","DOI":"10.1016\/S1473-3099(12)70261-X"},{"unstructured":"ResIn \u2010 Research Investments in Global Health. Available at:http:\/\/www.researchinvestments.org(accessed 4 July 2014).","key":"e_1_2_10_10_1"},{"volume-title":"The Global Burden of Disease: 2004 update","year":"2008","author":"World Health Organisation","key":"e_1_2_10_11_1"},{"doi-asserted-by":"publisher","key":"e_1_2_10_12_1","DOI":"10.1136\/bmjopen-2013-004600"},{"doi-asserted-by":"publisher","key":"e_1_2_10_13_1","DOI":"10.1111\/jvh.12123"},{"doi-asserted-by":"publisher","key":"e_1_2_10_14_1","DOI":"10.1016\/S0140-6736(13)61046-6"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12300","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T20:58:26Z","timestamp":1696280306000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,22]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/jvh.12300"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12300","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"type":"print","value":"1352-0504"},{"type":"electronic","value":"1365-2893"}],"subject":[],"published":{"date-parts":[[2014,8,22]]}}}